Clinical trial
A Phase II Study Evaluating Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors for Prevention of GVHD
NCT02220985 is registered in ClinicalTrials.gov with Fred Hutchinson Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Study Evaluating Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors for Prevention of GVHD
- Lead sponsor
- Fred Hutchinson Cancer Center
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- March 23, 2015
- Completion date
- May 1, 2025
- Enrollment
- 84 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
accelerated phase chronic myelogenous leukemia, bcr-abl1 positive, acute biphenotypic leukemia, acute leukemia of ambiguous lineage, acute lymphoblastic leukemia in remission, acute myeloid leukemia in remission, acute undifferentiated leukemia, allogeneic hematopoietic stem cell transplant recipient, blast phase chronic myelogenous leukemia, bcr-abl1 positive, blastic plasmacytoid dendritic cell neoplasm, childhood acute lymphoblastic leukemia in remission, childhood acute myeloid leukemia in remission, donor, lymphoblastic lymphoma, myelodysplastic syndrome with excess blasts, myelodysplastic syndrome with excess blasts-1, myelodysplastic syndrome with excess blasts-2, recurrent acute lymphoblastic leukemia, recurrent acute myeloid leukemia, recurrent childhood acute lymphoblastic leukemia, recurrent childhood acute myeloid leukemia, recurrent chronic myelogenous leukemia, bcr-abl1 positive, refractory acute lymphoblastic leukemia, refractory acute myeloid leukemia